Efficacy and safety of camrelizumab plus apatinib in patients with advanced esophageal squamous cell carcinoma previously treated with immune checkpoint inhibitors (CAP 02 Re-challenge): A single-arm, phase II study
European Journal of Cancer · 2024-11 · 212 · 114328
DOI: 10.1016/j.ejca.2024.114328 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift European Journal of Cancer, 2024-11. Verfasst von Xiangrui Meng und 40 weiteren Autor:innen. Beteiligte Einrichtung: The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Esophageal Neoplasms, Pyridines, Esophageal Squamous Cell Carcinoma. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: Jiangsu Hengrui Pharmaceuticals Co Ltd.
Abstract (Originalsprache)
BACKGROUND: With the increasing use of immune checkpoint inhibitors (ICIs) in advanced esophageal squamous cell carcinoma (ESCC), there remains an unmet need for options to address disease progression after prior ICIs. This single-arm phase II study evaluated the efficacy and safety of re-challenge with camrelizumab plus apatinib in patients with advanced ESCC who were previously treated with ICIs. METHODS: This study enrolled patients aged 18-75 years with unresectable locally advanced, locally recurrent, or distant metastatic ESCC who received prior ICIs. Patients received intravenous camrelizumab 200 mg every 2 weeks and oral apatinib 250 mg daily until disease progression, unacceptable toxicity, or consent withdrawal. The primary endpoint was the investigator-assessed confirmed objective response rate (ORR). RESULTS: Between September 1, 2021 and March 29, 2023, 49 eligible patients were enrolled and received treatment. Among the 49 patients, the confirmed ORR was 10.2 % (95 % CI 3.4-22.2), the disease control rate (DCR) was 69.4 % (54.6-81.7), the median progression-free survival (PFS) was 4.6 months (95 % CI 3.8-6.5) and overall survival (OS) was 7.5 months (5.5-13.6). Grade ≥ 3 treatment-related adverse events occurred in 17 patients (34.7 %). No treatment-related deaths occurred. CONCLUSIONS: This study showed that the confirmed ORR was modest and did not reach clinically meaningful improvement for patients with ESCC who were previously treated with ICIs, with a manageable safety profile.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
- Anyang Tumor Hospital, Anyang, Henan, China.
- Xinyang Tumor Hospital, Xinyang, Henan, China.
- The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, China.
- The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, China.
- The First Affiliated Hospital of Nanyang Medical College, Nanyang, Henan, China.
Förderung
- Jiangsu Hengrui Pharmaceuticals Co Ltd
Zitieren
APA
Meng, X., Wang, J., Xia, J., Wu, T., Luo, Z., Hong, Y., Lu, P., Guo, Y., Ji, Y., Zhang, M., Yang, L., Cheng, P., Liang, W., Shan, Z., Zhou, Y., Wang, M., Lu, T., Song, M., Zong, H., …, & Wang, F. (2024). Efficacy and safety of camrelizumab plus apatinib in patients with advanced esophageal squamous cell carcinoma previously treated with immune checkpoint inhibitors (CAP 02 Re-challenge): A single-arm, phase II study. European Journal of Cancer, 212, 114328. https://doi.org/10.1016/j.ejca.2024.114328
Vancouver
Meng X, Wang J, Xia J, Wu T, Luo Z, Hong Y, et al. Efficacy and safety of camrelizumab plus apatinib in patients with advanced esophageal squamous cell carcinoma previously treated with immune checkpoint inhibitors (CAP 02 Re-challenge): A single-arm, phase II study. European Journal of Cancer. 2024;212:114328. doi:10.1016/j.ejca.2024.114328
BibTeX
@article{Meng2024,
author = {Meng, Xiangrui and Wang, Junsheng and Xia, Jin and Wu, Tao and Luo, Zhiquan and Hong, Yonggui and Lu, Ping and Guo, Yanzhen and Ji, Yinghua and Zhang, Min and Yang, Liuzhong and Cheng, Peng and Liang, Wenchang and Shan, Zhengzheng and Zhou, Yue and Wang, Mingyue and Lu, Taiying and Song, Min and Zong, Hong and Song, Lijie and Wang, Wenkang and Guan, Lulu and Li, Yanke and Xing, Jianxiang and Xing, Siyuan and Wu, Han and Chu, Jingwen and Luo, Xi and Lu, Yao and Xin, Dao and Li, Aijia and Jiang, Binghua and Li, Shenglei and Jiang, Guozhong and Fan, Qingxia and Zhao, Feng and Zheng, Rongrong and Zhu, Wenqing and Hou, Zhiguo and Jia, Yun and Wang, Feng},
title = {Efficacy and safety of camrelizumab plus apatinib in patients with advanced esophageal squamous cell carcinoma previously treated with immune checkpoint inhibitors (CAP 02 Re-challenge): A single-arm, phase II study},
journal = {European Journal of Cancer},
year = {2024},
volume = {212},
pages = {114328},
doi = {10.1016/j.ejca.2024.114328}
}
EUVIMED